Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | APP | P05067 | 1/20 | 0.66 |
| ▸ | INSR | P06213 | 1/20 | 0.66 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ATP4A | P20648 | 15/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825345 | 1.00 | MEN1 (0.66) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL29559249 | 0.87 | MEN1 (0.77) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL319385 | 0.87 | MEN1 (0.77) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL319386 | 0.87 | MEN1 (0.77) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL6493243 | 0.87 | MEN1 (0.70) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL6493241 | 0.87 | MEN1 (0.70) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL13936229 | 0.85 | ATP4A (0.66) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL8034148 | 0.85 | RAB9A (0.60) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL17081873 | 0.83 | MEN1 (0.71) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL4017956 | 0.83 | RAB9A (0.54) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4063894-A | CHROMOGEN, HYDROPEROXIDE, THIAZOLE | SHIONOGI & CO., LTD. (JA) | 1977-12-20 | — | — | US | claimed |
| US-12092643-B2 | Detecting targets using mass tags and mass spectrometry | Ventana Medic Systems, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20210063411-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MED SYST INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10883999-B2 | Detecting targets using mass tags and mass spectrometry | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190004061-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MED SYST INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-10078083-B2 | Detecting targets using mass tags and mass spectrometry | VENTANA MEDICAL SYSTEMS, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-2588144-B1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MED SYST INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20160139143-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9291597-B2 | Detecting targets using mass tags and mass spectrometry | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20130122516-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. | 2013-05-16 | — | — | US | disclosed |
| EP-2588144-A2 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | Ventana Medical Systems, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003478-A2 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20050260126-A1 | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein | BF RESEARCH INSTITUTE (JP) | 2005-11-24 | — | — | US | disclosed |
| US-4063894-A | CHROMOGEN, HYDROPEROXIDE, THIAZOLE | SHIONOGI & CO., LTD. (JA) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260126-A1 | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein | PRNP, PRPH, PCNP | MEN1 3565/4885MAPT 7/4885KMT2A 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.